View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsNeovasc 향후 성장Future 기준 점검 0/6핵심 정보n/a이익 성장률n/aEPS 성장률Medical Equipment 이익 성장17.2%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트10 Feb 2023최근 향후 성장 업데이트Price Target Changed • Nov 16Price target decreased to US$18.00Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year.Price Target Changed • Apr 27Price target increased to US$5.00Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year.Price Target Changed • Jul 03Price target increased to US$5.00Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year.모든 업데이트 보기Recent updatesPrice Target Changed • Nov 16Price target decreased to US$18.00Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year.Reported Earnings • Nov 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$3.00 loss per share (further deteriorated from US$2.79 loss in 3Q 2021). Net loss: US$8.23m (loss widened 9.2% from 3Q 2021). Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 6.4%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Aug 25Independent Director recently bought US$76k worth of stockOn the 19th of August, Douglas Janzen bought around 10k shares on-market at roughly US$7.63 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months.Reported Earnings • Aug 12Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$3.29 loss per share (up from US$3.35 loss in 2Q 2021). Net loss: US$8.98m (flat on 2Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 39%. Over the next year, revenue is forecast to grow 309%, compared to a 6.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Seeking Alpha • Aug 11Neovasc GAAP EPS of -$3.29 misses by $0.93, revenue of $0.82M beats by $0.13MNeovasc press release (NASDAQ:NVCN): Q2 GAAP EPS of -$3.29 misses by $0.93. Revenue of $0.82M (+30.2% Y/Y) beats by $0.13M.Seeking Alpha • Jul 05Neovasc expands direct sales operations to include the UKNeovasc (NASDAQ:NVCN) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022. The company has hired its first two direct employees in England and plans future growth in the sales team as the commercial requirements increase. The expansion is driven by NICE guidelines and enhanced reimbursement for the Neovasc Reducer™. “We are now poised to provide even deeper support with a full-time dedicated team in the U.K. and intend to continue to invest in clinical research and field personnel to support patients, physicians, and hospitals.” said Fred Colen, Neovasc President and CEO.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$3.75 loss per share (down from US$1.11 loss in 1Q 2021). Net loss: US$10.2m (loss widened 369% from 1Q 2021). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 200%. Over the next year, revenue is forecast to grow 425%, compared to a 8.8% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target increased to US$5.00Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year.Reported Earnings • Mar 13Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.40 loss per share (up from US$1.72 loss in FY 2020). Net loss: US$24.9m (loss narrowed 13% from FY 2020). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 212%, compared to a 10% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 135% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Dec 15Chief Operating Officer recently bought US$79k worth of stockOn the 9th of December, William Little bought around 150k shares on-market at roughly US$0.53 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$7.54m (loss narrowed 26% from 3Q 2020).Recent Insider Transactions • Aug 21Independent Director recently bought US$76k worth of stockOn the 19th of August, Douglas Janzen bought around 100k shares on-market at roughly US$0.76 per share. In the last 3 months, they made an even bigger purchase worth US$94k. Insiders have collectively bought US$305k more in shares than they have sold in the last 12 months.Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$9.03m (loss narrowed 9.0% from 2Q 2020).Price Target Changed • Jul 03Price target increased to US$5.00Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year.Recent Insider Transactions • Jun 24Independent Director recently bought US$87k worth of stockOn the 22nd of June, Douglas Janzen bought around 100k shares on-market at roughly US$0.87 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$136k more in shares than they have sold in the last 12 months.Reported Earnings • May 09First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020)First quarter 2021 results: Net loss: US$2.17m (loss narrowed 47% from 1Q 2020).Reported Earnings • Mar 14Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$1.96m (down 6.4% from FY 2019). Net loss: US$28.7m (loss narrowed 18% from FY 2019). Over the last 3 years on average, earnings per share has increased by 129% per year but the company’s share price has fallen by 78% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 14Revenue and earnings miss expectationsRevenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 136%, compared to a 21% growth forecast for the Medical Equipment industry in the US.Is New 90 Day High Low • Jan 27New 90-day high: US$1.36The company is up 28% from its price of US$1.06 on 28 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$19.91 per share.Is New 90 Day High Low • Dec 09New 90-day low: US$0.72The company is down 67% from its price of US$2.17 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 13New 90-day low: US$0.75The company is down 66% from its price of US$2.17 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 225%, compared to a 16% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.51 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: US$626.4k (up 25% from 3Q 2019). Net loss: US$10.2m (loss widened 65% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 91% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 24New 90-day low: US$2.03The company is down 22% from its price of US$2.60 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.이익 및 매출 성장 예측NasdaqCM:NVCN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202310-23N/AN/A112/31/20224-41-25-25N/A9/30/20223-34-24-24N/A6/30/20223-33-25-25N/A3/31/20223-33-26-25N/A12/31/20213-25-27-27N/A9/30/20212-23-30-29N/A6/30/20212-26-31-31N/A3/31/20212-27-32-31N/A12/31/20202-29-30-29N/A9/30/20202-37-29-29N/A6/30/20202-33-27-27N/A3/31/20202-31-25-25N/A12/31/20192-35-24-24N/A9/30/20192-11-24-24N/A6/30/20192-20-23-23N/A3/31/20192-61-24-24N/A12/31/20182-108-23-23N/A9/30/20182-125-141-141N/A6/30/20183-115-140-140N/A3/31/20184-71-138-138N/A12/31/20175-22-139-139N/A9/30/2017719-22-21N/A6/30/20179-5-29-28N/A3/31/20179-83-36-35N/A12/31/201610-86-40-40N/A9/30/20169-131N/A-39N/A6/30/20168-110N/A-35N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NVCN 의 예상 수익 증가율이 절약률(2.1%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: NVCN 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: NVCN 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: NVCN 의 수익이 US 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: NVCN 의 수익이 연간 20%보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NVCN의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/04/13 19:24종가2023/04/10 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Neovasc Inc.는 9명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David DeanATB Cormark Historical (Cormark Securities)David MartinBloom Burton & Co.Jason MillsCanaccord Genuity6명의 분석가 더 보기
Price Target Changed • Nov 16Price target decreased to US$18.00Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year.
Price Target Changed • Apr 27Price target increased to US$5.00Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year.
Price Target Changed • Jul 03Price target increased to US$5.00Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year.
Price Target Changed • Nov 16Price target decreased to US$18.00Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year.
Reported Earnings • Nov 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$3.00 loss per share (further deteriorated from US$2.79 loss in 3Q 2021). Net loss: US$8.23m (loss widened 9.2% from 3Q 2021). Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 6.4%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Aug 25Independent Director recently bought US$76k worth of stockOn the 19th of August, Douglas Janzen bought around 10k shares on-market at roughly US$7.63 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 12Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$3.29 loss per share (up from US$3.35 loss in 2Q 2021). Net loss: US$8.98m (flat on 2Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 39%. Over the next year, revenue is forecast to grow 309%, compared to a 6.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Seeking Alpha • Aug 11Neovasc GAAP EPS of -$3.29 misses by $0.93, revenue of $0.82M beats by $0.13MNeovasc press release (NASDAQ:NVCN): Q2 GAAP EPS of -$3.29 misses by $0.93. Revenue of $0.82M (+30.2% Y/Y) beats by $0.13M.
Seeking Alpha • Jul 05Neovasc expands direct sales operations to include the UKNeovasc (NASDAQ:NVCN) has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022. The company has hired its first two direct employees in England and plans future growth in the sales team as the commercial requirements increase. The expansion is driven by NICE guidelines and enhanced reimbursement for the Neovasc Reducer™. “We are now poised to provide even deeper support with a full-time dedicated team in the U.K. and intend to continue to invest in clinical research and field personnel to support patients, physicians, and hospitals.” said Fred Colen, Neovasc President and CEO.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$3.75 loss per share (down from US$1.11 loss in 1Q 2021). Net loss: US$10.2m (loss widened 369% from 1Q 2021). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 200%. Over the next year, revenue is forecast to grow 425%, compared to a 8.8% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target increased to US$5.00Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year.
Reported Earnings • Mar 13Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.40 loss per share (up from US$1.72 loss in FY 2020). Net loss: US$24.9m (loss narrowed 13% from FY 2020). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 212%, compared to a 10% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 135% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Dec 15Chief Operating Officer recently bought US$79k worth of stockOn the 9th of December, William Little bought around 150k shares on-market at roughly US$0.53 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$7.54m (loss narrowed 26% from 3Q 2020).
Recent Insider Transactions • Aug 21Independent Director recently bought US$76k worth of stockOn the 19th of August, Douglas Janzen bought around 100k shares on-market at roughly US$0.76 per share. In the last 3 months, they made an even bigger purchase worth US$94k. Insiders have collectively bought US$305k more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$9.03m (loss narrowed 9.0% from 2Q 2020).
Price Target Changed • Jul 03Price target increased to US$5.00Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year.
Recent Insider Transactions • Jun 24Independent Director recently bought US$87k worth of stockOn the 22nd of June, Douglas Janzen bought around 100k shares on-market at roughly US$0.87 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$136k more in shares than they have sold in the last 12 months.
Reported Earnings • May 09First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020)First quarter 2021 results: Net loss: US$2.17m (loss narrowed 47% from 1Q 2020).
Reported Earnings • Mar 14Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$1.96m (down 6.4% from FY 2019). Net loss: US$28.7m (loss narrowed 18% from FY 2019). Over the last 3 years on average, earnings per share has increased by 129% per year but the company’s share price has fallen by 78% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 14Revenue and earnings miss expectationsRevenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 136%, compared to a 21% growth forecast for the Medical Equipment industry in the US.
Is New 90 Day High Low • Jan 27New 90-day high: US$1.36The company is up 28% from its price of US$1.06 on 28 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$19.91 per share.
Is New 90 Day High Low • Dec 09New 90-day low: US$0.72The company is down 67% from its price of US$2.17 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 13New 90-day low: US$0.75The company is down 66% from its price of US$2.17 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 225%, compared to a 16% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.51 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: US$626.4k (up 25% from 3Q 2019). Net loss: US$10.2m (loss widened 65% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 91% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 24New 90-day low: US$2.03The company is down 22% from its price of US$2.60 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.